Pricing Log in Create free account
Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Charles River Laboratories International, Inc. (CRL) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Charles River Laboratories International, Inc. (CRL) trades at a EV/EBITDA of 30.4×. Over the past ten years it has ranged from 9.3× (April 2025) to 33.1× (September 2021); the current reading is higher than 99% of that period. That is above the Diagnostics & Research industry median of 24.3× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 19.9× 38.77%
FY2024 14.3× (7.06%)
FY2023 15.4× 8.56%
FY2022 14.2× (43.20%)
FY2021 25.0× 18.24%
FY2020 21.2× 27.84%
FY2019 16.6× 18.36%
FY2018 14.0× (5.89%)
FY2017 14.9× 14.82%
FY2016 12.9× (12.97%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 24.1× 29.18%
Mar 2026 18.6× (6.31%)
Dec 2025 19.9× 61.00%
Sep 2025 12.4× (0.98%)
42 more quarters

Against its own ten years

Low 9.3× High 33.1×
Ten-year median 15.0×
Current reading's percentile 99

EV/EBITDA against peers

Company EV/EBITDA
TWST Twist Bioscience Corporation compare n/m
GH Guardant Health, Inc. compare n/m
DGX Quest Diagnostics Incorporated compare 14.1×
LH Labcorp Holdings Inc. compare 14.5×
QGEN QIAGEN N.V. compare 15.9×
ICLR ICON PLC compare 23.3×
RVTY Revvity Inc. compare 24.8×
MEDP Medpace Holdings, Inc. compare 27.9×
CRL Charles River Laboratories International, Inc. 30.4×
Diagnostics & Research industry median 24.3×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on CRL